Ameriprise Financial Inc. Has $39.90 Million Stock Holdings in The Clorox Company (NYSE:CLX)

Ameriprise Financial Inc. increased its holdings in The Clorox Company (NYSE:CLX - Free Report) by 14.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 245,686 shares of the company's stock after purchasing an additional 31,624 shares during the period. Ameriprise Financial Inc. owned approximately 0.20% of Clorox worth $39,902,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Integral Investment Advisors Inc. raised its position in Clorox by 4.1% in the fourth quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company's stock worth $279,000 after purchasing an additional 67 shares in the last quarter. HCR Wealth Advisors grew its stake in Clorox by 1.0% during the fourth quarter. HCR Wealth Advisors now owns 6,870 shares of the company's stock worth $1,116,000 after buying an additional 68 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its stake in Clorox by 6.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company's stock worth $218,000 after buying an additional 77 shares during the last quarter. Wedbush Securities Inc. grew its stake in Clorox by 1.2% during the fourth quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock worth $1,238,000 after buying an additional 94 shares during the last quarter. Finally, Brooklyn Investment Group grew its stake in Clorox by 163.8% during the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company's stock worth $25,000 after buying an additional 95 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company's stock.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the purchase, the director now owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.57% of the company's stock.

Analysts Set New Price Targets

CLX has been the topic of several research analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. DA Davidson decreased their price objective on shares of Clorox from $171.00 to $169.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. UBS Group decreased their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Morgan Stanley decreased their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Barclays decreased their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research note on Wednesday, May 7th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $151.23.

Clorox Price Performance

CLX opened at $134.79 on Monday. The Clorox Company has a one year low of $127.60 and a one year high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The company's 50 day simple moving average is $142.37 and its 200-day simple moving average is $154.03. The stock has a market capitalization of $16.60 billion, a P/E ratio of 36.83, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the previous year, the business posted $1.71 earnings per share. Clorox's revenue was down 8.0% compared to the same quarter last year. Sell-side analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd were paid a $1.22 dividend. The ex-dividend date of this dividend was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a yield of 3.62%. Clorox's payout ratio is presently 87.61%.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.